Grace Dy MD
Grace Dy
MD
Professor
Jacobs School of Medicine & Biomedical Sciences
Specialty/Research Focus
Oncology; Signal Transduction
Education and Training:
- Fellowship, Hematology-Oncology, Mayo Clinic College of Medicine (2007)
- Residency, Internal Medicine, Mayo Graduate School of Medicine (2003)
- Internship, Chinese General Hospital (1999)
- MD, University of St. Tomas, Philippines (1998)
Employment:
- Associate Professor of Oncology, Medicine, Roswell Park Cancer Institute Roswell Park Cancer Institute (2016-present)
Awards and Honors:
- NCCN Correlative Sciences Grant Award (2009)
- International Association for the Study of Lung Cancer Fellowship Award (2009)
- Oncology Outstanding Achievement Award (2007)
- William H.J. Summerskilll Award (2007)
- 2005 Annual Meeting Merit Award - American Society of Clinical Oncology (2005)
- 2005 GI Symposium Merit Award - American Society of Clinical Oncology (2005)
- Outstanding Resident Research Award (2003)
- Rank 1 out of 404 Graduating Medical Students (1999)
- Most Outstanding Intern (1999)
- Summa cum laude (1998)
Journal Articles:
- Yendamuri S, Battoo A, Dy G, Chen H, Gomez J, Singh AK, Hennon M, Nwogu CE, Dexter EU, Huang M, Picone A, Demmy TL. (2017) Transcervical Extended Mediastinal Lymphadenectomy: Experience From a North American Cancer Center. Ann Thorac Surg (Nov), 104(5): 1644-1649.
- Nwogu CE, Mahoney M, Okoye I, Ejiogu K, George S, Dy G, Jimoh M, Salako O, Ilegbune O, Chugani B, Ezeome E, Popoola AO, Michalek AM. (2016) Role of Private Enterprise in Cancer Control in Low to Middle Income Countries. J Cancer Epidemiol (Dec), 2016: 7121527-7121527.
- Nwogu C, Mahoney M, George S, Dy G, Hartman H, Animashaun M, Popoola A, Michalek A. (2014) Promoting cancer control training in resource limited environments: lagos, Nigeria. J Cancer Educ (Mar), 29(1): 14-18.
- Al Ustwani O, Lohr J, Dy G, Levea C, Connolly G, Arora P, Iyer R. (2014) Eculizumab Therapy for Gemcitabine Induced Hemolytic Uremic Syndrome: Case Series and Concise Review. J Gastrointest Oncol (Feb), 5(1): 30-33.
- Dy GK, Mandrekar SJ, Nelson GD, Meyers JP, Adjei AA, Ross HJ, Ansari RH, Lyss AP, Stella PJ, Schild SE, Molina JR, Adjei AA, Dy G. (2013) A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528. J Thorac Oncol (Jan), 8(1): 79-88.
- Dy GK, Infante JR, Eckhardt SG, Novello S, Ma WW, Jones SF, Huff A, Wang Q, Suttle AB, Ottesen LH, Adjei AA, Burris HA, Dy G. (2012) Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib. Invest New Drugs (Nov).
- Infante JR, Novello S, Ma WW, Dy GK, Bendell JC, Huff A, Wang Q, Suttle AB, Allen R, Xu CF, Ottesen LH, Burris HA, Adjei AA, Dy G. (2012) Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors. Invest New Drugs (Nov).
- Reungwetwattana T, Molina JR, Mandrekar SJ, Allen-Ziegler K, Rowland KM, Reuter NF, Luyun RF, Dy GK, Marks RS, Schild SE, Jett JR, Adjei AA, Dy G. (2012) Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. J Thorac Oncol (May), 7(5): 919-922.
- Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, Maniar M, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A, Dy G. (2012) Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clin Cancer Res (Apr), 18(7): 2048-2055.
- Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, Camidge DR. (2012) A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. J Thorac Oncol (Feb), 7(2): 419-426.
- Lorusso PM, Jimeno A, Dy G, Adjei A, Berlin J, Leichman L, Low JA, Colburn D, Chang I, Cheeti S, Jin JY, Graham RA. (2011) Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res (Sep), 17(17): 5774-5782.
- Dy G. (2010) Novel taxanes/epothilones. J Thorac Oncol (Dec), 5(12 Su): 490-491.
- Dy G. (2010) MEK/MAPK inhibitors. J Thorac Oncol (Dec), 5(12 Su): 474-475.
- Dy G. (2010) SRC inhibitors. J Thorac Oncol (Dec), 5(12 Su): 466-467.
- Dy GK, Mandrekar S, Peethambaram PP, Okuno SH, Croghan GC, Hanson LJ, Furth A, Adjei AA, Dy G. (2005) A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer. Cancer Chemother Pharmacol (Dec), 56(6): 623-628.
- Dy GK, Suri A, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Atherton PJ, Hanson LJ, Burch PA, Rubin J, Erlichman C, Adjei AA, Dy G. (2005) A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors. Cancer Chemother Pharmacol (Jun), 55(6): 522-530.
- Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA, Dy G. (2005) A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res (May), 11(9): 3410-3416.
- Dy GK, Bruzek LM, Croghan GA, Mandrekar S, Erlichman C, Peethambaram P, Pitot HC, Hanson LJ, Reid JM, Furth A, Cheng S, Martell RE, Kaufmann SH, Adjei AA, Dy G. (2005) A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer. Clin Cancer Res (Mar), 11(5): 1877-1883.
- Dy GK, Bekele L, Hanson LJ, Furth A, Mandrekar S, Sloan JA, Adjei AA, Dy G. (2004) Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol (Dec), 22(23): 4810-4815.
- David O, Jett J, LeBeau H, Dy G, Hughes J, Friedman M, Brody AR. (2004) Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res (Oct), 10(20): 6865-6871.
- Haluska P, Dy GK, Adjei AA, Dy G. (2002) Farnesyl transferase inhibitors as anticancer agents. Eur J Cancer (Sep), 38(13): 1685-1700.
- Dy GK, Adjei AA, Dy G. (2002) Novel targets for lung cancer therapy: part II. J Clin Oncol (Jul), 20(13): 3016-3028.
- Dy GK, Adjei AA, Dy G. (2002) The role of farnesyltransferase inhibitors in lung cancer therapy. Clin Lung Cancer (Jul), 4(1): 57-62.
- Dy GK, Adjei AA, Dy G. (2002) Novel targets for lung cancer therapy: part I. J Clin Oncol (Jun), 20(12): 2881-2894.
- Dy GK, Haluska P, Adjei AA, Dy G. (2001) Novel pharmacological agents in clinical development for solid tumours. Expert Opin Investig Drugs (Dec), 10(12): 2059-2088.
Professional Memberships:
- Active Member - American Association for Cancer Research; Active Member - American Association for Cancer Research (2007–present)
- Active Member - American Society of Clinical Oncology; Active Member - American Society of Clinical Oncology (2007–present)
- International Association for the Study of Lung Cancer; Regular Member - International Association for the Study of Lung Cancer (2007–present)
- Associate Member - American Association for Cancer Research; Associate Member - American Association for Cancer Research (2004–2006)
- Associate Member - American Society of Clinical Oncology; Associate Member - American Society of Clinical Oncology (2004–2006)
Service Activities:
- DBT India Alliance; India Alliance Fellowship; Application on DNA helicases by Dibyendu Banerjee;; Ad Hoc Reviewer (2014)
- RPCI Policy and Procedures Committee; Committee Member (2014–present)
- Hematology-Oncology Fellowship Clinical Competency Committee; Committee Member (2014–present)
- Fund for Scientific Research (F.R.S.-FNRS); Credits and Projects 2013; Reviewed the proposal by C. PEQUEUX: Role of estrogens in carcinogenesis and cancer progression in bronchial carcinoma;; Ad Hoc Reviewer (2013)
- Medical Staff Executive Committee; Committee Member (2013–present)
- Fund for Scientific Research (F.R.S.-FNRS); Fellowship and Projects; Reviewed proposal by S. Ocak in February 2013 entitled: Role of focal adhesion kinase (FAK) in the invasive phenotype of small-cell lung cancer (SCLC) and analysis of FAK signaling in SCLC by quantitative phosphoproteomics;; Ad Hoc Reviewer (2013)
- Hematology-Oncology Fellowship Core Curriculum; Acting Director (2011–present)
- Phase I Data and Safety Monitoring Committee; Co-Director (2007–present)
- Respiratory Committee (ACTION) Cooperative group; Committee Member (2007–present)
- Scientific Review Committee; Committee Member (2007–present)